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Abstract
Study Objective: Narcolepsy type 1 (NT1) is considered a chronic, incurable disease. Excessive daytime sleepiness (EDS) is typically 
the most troublesome symptom, and more difficult to control by pharmacologic treatment than cataplexy. Although many NT1 
patients are monitored by regular follow-ups, the purported relentless persistence of EDS has rarely been the object of longitudinal 
studies.
Methods: Retrospective analysis of 26 well-defined hypocretin-deficient NT1 patients who underwent longitudinal assessments of 
Epworth sleepiness scale (ESS) scores under stable pharmacotherapy. We present detailed case reports of four patients with unusual 
spontaneous improvement.
Results: Over a mean observation period of 5 years, changes in ESS scores between first and last examination were ≤4 points 
in 19 patients (73%). Three patients deteriorated by 5 points, four patients ameliorated by 7–11 points. Among the latter, 
subjective sleepiness resolved in all four patients, and three of them continued showing ESS scores <11 after cessation of their 
pharmacotherapy. Without therapy, two patients did not fulfill anymore the ICSD-3 multiple sleep latency test criteria (mean sleep 
latency >8 minutes), one of whom did not fall asleep during maintenance of wakefulness test. Multiple linear regression analysis 
identified higher cerebrospinal fluid (CSF) hypocretin level (p < 0.001) and absence of fragmented nighttime sleep (p = 0.001) as 
independent associates of EDS improvement.
Conclusions: The longitudinal course of NT1-related sleepiness is not invariably stable, but included spontaneous deterioration 
or improvement in 27%. Spontaneous improvement can persist after treatment discontinuation and resemble remission. Milder 
hypocretin deficiency and good nighttime sleep may predict a more favorable disease course.
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Statement of Significance
This study on longitudinal clinical evolution in narcolepsy type 1 (NT1) suggests that a significant minority of patients can improve 
spontaneously akin to clinical remission, and that measurable cerebrospinal fluid (CSF) hypocretin levels and consolidated night-
time sleep may constitute positive prognostic factors. Where available, repetitive measures of hypocretin demonstrated a pro-
gressive decline despite clinical improvement, indicating compensatory mechanisms distinct from the hypocretin system. These 
findings challenge the exclusive role of hypocretin deficiency in NT1 pathophysiology, question the classical view of NT1 as an 
incurable disease, and may stimulate new research on compensatory mechanisms. Moreover, a better characterization of patients 
with spontaneous improvement may have important prognostic and therapeutic implications.
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Introduction
The clinical course of narcolepsy type 1 (NT1) is classically 
considered as monophasic and non-remitting. The defining 
symptoms, excessive daytime sleepiness (EDS) and cataplexy, 
typically evolve acutely, although their onset may be separated 
by several months or even years [1]. Once established, both 
symptoms are thought to persist for a lifetime. This seems in 
accordance with the acute loss of >90% of hypocretin-producing 
neurons in the hypothalamus, causing irreversible hypocretin 
deficiency [2].
While this classical notion of a relentless persistence of NT1 
symptoms has been widely accepted, its natural course has 
rarely been the object of longitudinal studies [1–4]. Few anec-
dotic reports [7] and therapeutic clinical trials seem to confirm 
long-term stability of EDS [8–11]. However, since many patients 
had changes in type and dosage of their pharmacotherapy dur-
ing the observation period, it appears difficult to draw reliable 
conclusions on the natural evolution of symptoms. On the other 
hand, there is accumulating evidence for a more variable and 
dynamic disease course than traditionally assumed, especially 
at its onset. For instance, Pizza et al. [5] described in 21 drug-naïve 
children a heterogeneous natural evolution of NT1 symptoms 
with gradual changes in cataplexy phenomenology and sleep-
wake behavior over a mean follow-up of 2.1 years. In the same 
line, a case description suggests that NT1 can evolve progres-
sively over the years paralleled by declining cerebrospinal fluid 
(CSF) hypocretin levels [6]. Finally, while remission of symptoms 
has been noted to occur in patients diagnosed with NT2 and 
other hypersomnolence disorders [12, 13], such an unexpected 
disease course has not been described in NT1 patients [14].
Here, we retrospectively assessed the stability of EDS in 
well-defined hypocretin-deficient NT1 patients with constant 
therapy regimen over a mean observation period of 5 years. In 
addition, we present detailed case histories of NT1 patients with 
spontaneous improvement (n = 4), including sustained clinical 
remission (n = 3) that persisted after treatment withdrawal.
Methods
Inclusion criteria
We retrospectively evaluated 65 NT1 patients seen in the sleep 
clinic of the Department of Neurology, University Hospital 
Zurich, between 2004 and 2016. Inclusion criteria were a def-
inite diagnosis of NT1 according to the ICSD-3 criteria (AASM 
2014)  [15] with proven CSF hypocretin deficiency (<200 pg/ml 
according to Zurich standards), and a longitudinal follow-up 
under stable NT1 treatment of at least 12  months. The flow-
chart in Figure 1 illustrates the number of patients that had to 
be excluded from the final analysis. Briefly, we first excluded 
patients without CSF hypocretin analysis (n  =  6) or lack of 
informed consent (n  =  2). Next, we excluded 21 patients with 
too short (<1 year) follow-up period at our department. We did 
not exclude 10 NT1 patients despite changing therapy regimen 
during the follow-up, but analyzed them separately. Eventually, 
we included 36 well-defined NT1 patients with follow-up over at 
least 1 year, including 26 patients with stable therapy regimen. 
The Ethics Committee of the Canton of Zurich, specialized sub-
committee for Psychiatry, Neurology, Neurosurgery (BASEC No. 
2017-00875), approved the study protocol.
Diagnostic work-up of participants
We retrieved detailed clinical information from the patients’ 
medical records of the included 36 NT1 patients. Demographical 
characteristics comprised age, sex, body mass index (BMI). 
One patient was African, one was Asian, the remaining were 
Caucasians. Diagnostic work-up comprised in all patients a 
detailed interview (including information regarding cataplexy, 
sleep paralysis, hallucinations, nighttime sleep disturbances), 
2-week actigraphy, video-polysomnography and multiple sleep 
latency test (MSLT), analyzed according to slightly modified 
standard criteria, as described in previous work [16, 17]. Epworth 
sleepiness scale (ESS) determined subjective daytime sleepi-
ness. Baseline values of the Ullanlinna Narcolepsy Score [18] 
were available from all but two patients, and specific informa-
tion were retrieved regarding cataplexy characteristics and fre-
quency. All patients had definite cataplexy, and all had multiple 
sleep-onset rapid eye movement periods (SOREMPs) in their 
diagnostic MSLT. Human leukocyte antigen (HLA)-genotyping 
was available in 34 patients, all of them positive for the HLA-
DQB1*0602 haplotype. CSF hypocretin levels were analyzed as 
previously described [19]. Decrease in CSF hypocretin levels was 
labeled as undetectable if <30 pg/ml, and low if between 30 and 
200 pg/ml. At follow-up, we routinely assessed current medica-
tion and ESS scores as well as patient descriptions of changes in 
NT1 symptoms.
Observation period, outcome measures
For the main study population (n  =  26), the duration of the 
observation period was determined by the documentation of a 
steady therapy regimen and available ESS scores. The observa-
tion period ended if patients had no further follow-up in our 
clinic or when pharmacotherapy had to be changed. Of note, in 
order to identify patients with spontaneous improvement, the 
observation period continued in case of treatment cessation. 
Primary outcome measure was the change in ESS score between 
baseline and last examination on the same treatment or after 
treatment cessation (∆
ESS
). Thus, ESS values assessed while the 
patient was still on therapy, or after therapy cessation, counted 
together. We considered ESS changes of >4 points as significant, 
which is in agreement with a recent longitudinal population-
based study on daytime sleepiness [20]. Hence, we labeled a >4 
point increase in ESS score as spontaneous deterioration, and 
a >4 point decrease as spontaneous improvement. We defined 
clinical remission as the absence of NT1 symptoms for at least 
6 months after complete cessation of pharmacotherapy. In add-
ition, we performed a sub-analysis in 10 patients with variable 
NT1 treatment. To this end, we compared the first available ESS 
score on any type of EDS treatment with the last one (per defin-
ition on another type of treatment), and applied the same crite-
ria for judging the clinical course as mentioned above.
Statistical analysis
Statistical analyses were performed using SPSS (version 23). 
Group data were described by means and SDs. For normally 
distributed data, we applied Student’s t-test. We used Pearson 
correlation to assess “longitudinal stability” of ESS scores in 
the patient group with ∆
ESS
 ≤4 points. The paired samples t-test 
was applied to compare longitudinal ESS scores. To identify 
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predictors of improving ESS scores, we used stepwise multiple 
regression analysis with the following independent variables: 
Gender, age of onset of EDS, delay between EDS onset and diag-
nosis of NT1, ESS at presentation, presence of hypnogogic hal-
lucinations, sleep paralysis and disturbed nighttime sleep at 
presentation. Significance was accepted at p < 0.05.
Results
Longitudinal observation of 26 NT1 patients under 
stable therapy regimen
On average, the duration of the observational period was 
5  ±  3  years (range: 1–12  years), and started with a latency 
of 13  ±  11  years (range: 1–44  years) after disease onset, and 
9 ± 5 months (range: 2–26 months) after the last modification 
in pharmacotherapy. This lag between therapy adjustment and 
initiation of the observation period makes delayed treatment 
effects of stable pharmacotherapy, as observed for sodium oxy-
bate [21], unlikely. During the observation period, changes in 
ESS scores were ≤4 points in 19 patients (73%, stable disease), 
whereas ESS scores increased by 5 points in three patients (12%, 
spontaneous deterioration) and decreased by 7–11 points in four 
patients (15%, spontaneous improvement). In the 19 patients 
with minor ESS changes, stability was reflected by a strong cor-
relation between first and last ESS values (r  =  0.85, p  <  0.001). 
Table 1 shows the demographical and clinical characteristics of 
the three groups, as well as their pharmacotherapy during the 
observation period.
Correlates and predictors of sleepiness evolution
Positive changes (improvement) in ESS scores correlated with 
higher CSF hypocretin levels (r  =  0.66, p < 0.0005; Figure  2A). 
ESS scores at the beginning of the observation period did not 
differ between NT1 patients with detectable and undetect-
able CSF hypocretin levels (14.3 ± 2.6 vs. 13.2 ± 4.3, p = 0.53). At 
the end, however, ESS scores appeared unchanged in patients 
with undetectable CSF hypocretin levels (14.4 ± 4.8), but signifi-
cantly decreased in those with detectable CSF hypocretin levels 
(9.3 ± 4.9, p = 0.033) (Figure 2B).
Multiple linear regression analysis confirmed higher CSF 
hypocretin levels as independent associate of improving ESS 
scores (Table 2). In addition, absence of a complaint of disturbed 
nighttime sleep at baseline was independently associated with 
a more favorable evolution of ESS scores during the observation 
period.
Longitudinal observation of 10 NT1 patients with 
changing therapy regimen
Demographic and clinical data of the 10 patients with chan-
ging therapies (three females, seven males) were not differ-
ent from the 26 patients with stable treatment. Four patients 
(40%) had detectable and six patients (60%) had undetectable 
CSF-hypocretin levels. Treatment changes were restricted to 
pharmacotherapy in eight patients, with one change in three 
patients and two changes in five patients (due to insufficient 
efficacy in 40%, insufficient tolerability in 40%, or for unclear 
reasons in 20%). Two further patients had comorbid severe 
obstructive sleep apnea with additional adjustments of apnea 
therapy (changes of ventilation parameters of continuous posi-
tive airway pressure therapy in both cases, multilevel surgery 
in one case, mandibular advancement orthesis in one case). 
When comparing the means of the first documented ESS score 
on any type of EDS-specific therapy (15.0  ±  3.8) with the last 
one (14.4 ± 4.5), no significant change was identified (−0.6 ± 2.6, 
p > 0.05; mean time period 6.6 years, range 1–15 years). Only 
Figure 1. Overview of patient selection based on pre-defined inclusion criteria.
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Figure 2. Impact of cerebrospinal fluid (CSF) hypocretin levels at presentation on the longitudinal disease course of narcolepsy type 1. (A) Pearson correlation of CSF 
hypocretin levels (pg/ml) and change of ESS scores during the observation period (r = 0.66, p < 0.0005). (B) Comparison of mean ESS values at first versus last visit of 
the observation period, both for patients with low CSF hypocretin values (≥30 pg/ml, left panel) and for patients with undetectable hypocretin values (<30 pg/ml, right 
panel). The dashed black line indicates the cut-off for a “normal” ESS score (<11 points). The boxes show mean and SD. Green dots indicate the four patients who 
improved by >4 ESS points, red dots indicate the three patients who deteriorated by >4 points in ESS (dashed line for patient whose ESS remained <11 points, i.e. within 
a physiological range), black dots indicate the 19 patients with stable disease as defined by minor changes in ESS scores ≤4 points.
Table 1. Demographical and clinical characteristics of 26 NT1 patients with stable treatment
Stable values in ESS score 
(≤4 points)
Deterioration in ESS score  
(≥5 points)
Improvement in ESS score  
(≥5 points)
N 19 (73%) 3 (12%) 4 (15%)
Disease onset to observational period, years 12 ± 7 21 ± 19 13 ± 21
Duration of observational period, years 4.7 ± 3.2 2.4 ± 1.0 7.1 ± 3.3
∆
ESS score
 (range) 0.4 ± 2.1 (−2 to 4) 5.0 −8.8 ± 2.1 (−7 to −11)
Age at disease onset, years 24 ± 12 29 ± 19 28 ± 12
Female sex, n 12 1 2
 Body mass index, kg/m2 24.7 ± 5.0 28.2 ± 3.4 28.7 ± 3.5
 CSF hypocretin level, pg/ml 14 ± 31 0.0 88 ± 53
 Detectable CSF hypocretin, n 4 0 4
Treatment, n
 No pharmacotherapy 2 1 1
 Sodium oxybate (GHB) 11 0 1
 Stimulants (modafinil, methylphenidate) 12 1 2
 Antidepressants 7 1 0
Clinical characteristics at presentation, n
 Hypnagogic/hypnopompic hallucinations 10 1 1
 Sleep paralysis 12 1 2
 Disturbed nighttime sleep 14 3 2
 Cataplexy leading to falls 11 1 2
 Cataplexy occurring at least daily 11 1 0
 Cataplexy occurring at least weekly 6 0 3
 Cataplexy occurring less often than weekly 2 1 0
 No information on cataplexy available 0 1 1
 Ullanlinna Narcolepsy Score 25 ± 6 23 ± 6 19 ± 1
Polysomnography findings at presentation
 Sleep efficiency (sleep time), % 83.6 ± 21 64.7 ± 33 90.5 ± 7
 Arousal index, /hour 17.8 ± 21 9.5 ± 5.8 8.0 ± 5.8
 Nocturnal SOREMP, n 8 2 1
MSLT findings at presentation
 Mean sleep latency, min 1.8 ± 1.2 1.7 ± 1.7 2.5 ± 1.0
 Number of SOREMPs / number of naps 0.8 ± 0.2 0.5 ± 0.4 0.7 ± 0.2
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one patient exhibited a significant decrease of the ESS score 
from 15 to 8 points during a follow-up period of 15 years, but 
this improvement occurred after the addition of sodium oxy-
bate. The remaining nine patients showed minor ESS changes 
≤4 points.
Assuming that all 10 patients with therapy change had 
probably a stable natural disease course, the distribution of 
various courses changes to stable disease in 81%, deterioration 
in 8% and improvement in 11% of patients of all 36 subjects 
under study.
Detailed presentation of four NT1 patients with 
spontaneous improvement/remission
Patient 1 (male) presented to our department at the age of 
55 years. He described an acute onset of EDS and definite cata-
plexy, involving arms and legs but without falls, triggered by 
strong emotions, at age 15  years. He denied sleep paralysis, 
hypnagogic hallucinations and disturbed nighttime sleep, but 
reported episodes of automatic behavior during daytime. His 
EDS has caused several traffic accidents. CSF hypocretin level 
was 163 pg/ml, and he was found to carry the HLA-DQB1*06:02 
gene (Figure 3). Polysomnography showed a sleep latency to N2 
and R sleep of 4 minutes and 133 minutes, respectively, and a 
sleep efficiency of 82.4%. Mean sleep latency on MSLT was 3.0 
minutes, with two SOREMPs (sequence of sleep stages: non-
rapid eye movement sleep stage 1 - non-rapid eye movement 
sleep stage 2 - rapid eye movement sleep [N1-N2-R]). On 2-week 
actigraphy, there was no sign of an insufficient sleep syndrome 
or a circadian rhythm disorder (mean resting period 8 hours, 
stable circadian rhythm). Under regular modafinil treatment, 
ESS scores dropped from 22 to 18 points. Two years after treat-
ment initiation, at the age of 57  years, he reported complete 
cessation of cataplexy. Given further improvement of EDS, he 
started taking modafinil only when driving long distances or 
attending important meetings. Nevertheless, ESS scores (with-
out modafinil) gradually dropped in the following 10  years to 
8 points. Thus, at the age of 67  years, he claimed to be cured 
from narcolepsy. At that point, repeated MWTs (carried out with 
modafinil as required by the road traffic-licensing department) 
had shown stable improvement. A follow-up MSLT performed in 
drug-free condition, revealed a mean sleep latency of 8.5 min-
utes and one SOREMP. The precedent 2-week actigraphy yielded 
similar results as the initial examination at presentation with a 
regular mean resting period of 7 hours 43 minutes and no signs 
of a circadian rhythm disorder. A  follow-up lumbar puncture 
was performed showing a further decrease of CSF hypocretin 
levels to 121 pg/ml.
Patient 2 (male), presented in our clinic, aged 26 years, shortly 
after developing EDS and, 2 months later, cataplectic attacks that 
were triggered by laughter and involved his head and both legs, 
without causing falls. He denied sleep paralysis, disturbed night-
time sleep and hypnagogic hallucinations. His medical history 
was remarkable for severe traumatic brain injury at the age of 
12 years. CSF hypocretin level was 68 pg/ml, and he was found 
to carry the HLA-DQB1*06:02 gene. Polysomnography showed a 
sleep latency to N2 and R sleep of 4 minutes and 0.5 minutes, 
respectively, and a sleep efficiency of 95.6%. Mean sleep latency 
on MSLT was 3.9 minutes, with three SOREMPs (sequence of 
sleep stages in two naps N1-R, in one nap N1-N2-R). The prece-
dent 2-week actigraphy showed no signs of an insufficient sleep 
syndrome (mean resting period 7 hours 46 minutes) or a circa-
dian rhythm disorder. After initiation of modafinil, ESS scores 
decreased from 13 to 4 points, and he was able to remain awake 
on MWT. Few months later, at the age of 27 years, modafinil had 
to be stopped because of side effects (nausea, palpitations), but 
sleepiness did not return. Furthermore, cataplexy ceased com-
pletely and the patient refused to take further medication, as he 
felt cured from narcolepsy. At follow-up examinations, always 
in drug-free conditions, ESS scores were <10 points, he could 
stay awake on MWT and the MSLT improved with a mean sleep 
latency of 10.1 minutes (with two SOREMPs). CSF hypocretin lev-
els were undetectable in a second analysis at the age of 31 years.
Patient 3 (female), presented in our clinic at the age of 
60 years and reported progressive onset of EDS since age 41, fol-
lowed after 15  years by generalized cataplexy with secondary 
falls. She also suffered from daily hypnagogic hallucinations 
and fragmented nighttime sleep, but never experienced sleep 
paralysis. CSF hypocretin level was 82 pg/ml, and she was found 
to carry the HLA-DQB1*06:02 gene. Polysomnography showed a 
sleep latency to N2 and R sleep of 16 minutes and 75 minutes, 
respectively, and a sleep efficiency of 85.7%. She had episodes 
of somniloquia during R sleep, but muscle atonia during R sleep 
was otherwise preserved. Mean sleep latency on MSLT was 1.8 
minutes, with four SOREMPs (sleep stage sequence N1-N2-R in 
three naps, N1-R in one nap). Her ability to stay awake on MWT 
was severely impaired, with unintended sleep occurring after a 
mean latency of 2.1 minutes. Under low-dose treatment with 
sodium oxybate (2 × 1.5 g), she reported marked consolidation 
of nocturnal sleep, reduction in cataplexy frequency from 2–3×/
week to 1–2×/months, while hypnagogic hallucinations now 
occurred only once weekly. She also felt more alert during day-
time, as documented by mild amelioration of both subjective 
and objective sleepiness measures. Seven years later, at the age 
of 67 years, the patient noticed a spontaneous improvement of 
all NT1 symptoms despite unchanged treatment with 2 × 1.5 g 
sodium oxybate. ESS score decreased to 6 points, she had no 
longer any cataplectic attacks and only very rarely hypnagogic 
hallucinations. There was also a substantial improvement of 
mean sleep latency on MWT to 35 minutes.
Patient 4 (female) is a refugee from Eritrea, who presented 
to our clinic at the age of 21 years. She described fever and flu-
like symptoms during her escape through Sudan, and imme-
diately afterwards developed EDS and generalized cataplectic 
attacks precipitated by strong emotions 2  years earlier, at the 
age of 19 years. CSF hypocretin level was 39 pg/ml, and she was 
Table 2. Multiple linear regression model for coefficients of changes in ESS scores during the observational period
Dependent variable Significant coefficients Estimated effect (β) Standard error t p
∆
ESS score CSF hypocretin level [pg/ml] − 0.624 0.014 − 4.587 < 0.001
Disturbed nocturnal sleep 0.507 1.471 3.726 0.001
Additional coefficients included in the model were age at presentation, age at disease onset, duration of observational period, latency between disease onset and 
observational period, body mass index, and mean sleep latency on MSLT.
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found to carry the HLA-DQB1*06:02 gene. She denied sleep par-
alysis, disturbed nighttime sleep or hypnagogic hallucinations. 
Polysomnography showed a sleep latency to N2 and R sleep 
of 1.6 minutes and 106 minutes, respectively, and a sleep effi-
ciency of 98%. Mean sleep latency on MSLT was 1.5 minutes, 
with two SOREMPs (sleep stage sequence N1-N2-R). Because still 
breastfeeding, her treatment was limited to non-pharmacologic 
symptom management. In the following year, she reported 
a spontaneous improvement of EDS and cessation of cata-
plexy. She refused any pharmacotherapy, and felt cured from 
Figure 3. Overview of the longitudinal disease course of 4 patients with spontaneous improvement as assessed by (A) ESS, (B) MWT and (C) MSLT (cut-off for patho-
logical sleepiness: mean sleep latency < 8 minutes). Panel (D) displays the concentration of hypocretin in the cerebrospinal fluid (CSF) over time. *hypocretin con-
centration unmeasurable (<30 pg/ml). Open symbols indicate examination without pharmacotherapy for narcolepsy; filled symbols indicate examination under the 
pharmacotherapy for narcolepsy. For patient 1, the MWT was carried out with modafinil medication (filled symbols), which was a requirement of the road traffic licens-
ing department. Otherwise, he was drug-free in everyday life, reflected by open symbols for the ESS questionnaire and MSLT.
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narcolepsy. Her last recorded ESS score was 4 points at the age 
of 24 years. She does not have a driver’s license.
Discussion
During the chronic disease phase, every fourth NT1 patient 
reported considerable changes in subjective sleepiness despite 
stable therapy regimen, including both deterioration (n = 3) and 
spontaneous improvement (n = 4). Most strikingly, three patients 
continued showing ESS scores <11 without pharmacotherapy, 
and improvement of sleepiness was paralleled by a normalized 
MSLT in two patients. Multiple regression analysis suggested 
milder CSF hypocretin deficiency and good nighttime sleep as 
predictors of spontaneous improvement in EDS. Interestingly, 
when repetitive CSF-hypocretin measurements were performed 
in two patients, we found a discrepancy between clinical ameli-
oration and progressive hypocretin deficiency, which chal-
lenges the classical concept of hypocretin as the exclusive NT1 
biomarker.
Although classified as chronic disease with stable course, 
“clinical stability” in NT1 has actually never been defined, and 
longitudinal data on symptom severity under steady ther-
apy are rare. Our observation now suggests that sleepiness is 
indeed stable over the years in a majority of NT1 patients, as 
indicated by a strong Pearson correlation between first and last 
ESS values of 0.85. This number is identical to published data on 
test-retest reliability of the ESS in healthy subjects and patients 
with sleep apnea, also expressed by means of Pearson correla-
tions [22]. Sure, our definition of long-term stability in NT1 can 
be criticized as purely academic, and the labeling of “deteri-
oration” in three NT1 patients may appear inappropriate and 
without clinical relevance, possibly reflecting only physiological 
fluctuations of sleepiness rather than true exacerbation of the 
NT1 phenotype. Moreover, several other factors may aggravate 
(e.g. psychiatric comorbidities) or alleviate (e.g. behavioral cop-
ing strategies) NT1 symptoms.
The observation of spontaneous improvement akin to clin-
ical remission, on the other hand, is more intriguing, and cer-
tainly of clinical interest. It cannot be downplayed to mere 
physiological fluctuations, because the changes were too pro-
nounced and accompanied by remission of all other NT1 symp-
toms. Subjective sleepiness did not reemerge in two patients 
after withdrawal of their pharmacotherapy, and these patients 
eventually even claimed being cured. Without any pharmaco-
therapy, two patients had a mean sleep latency on MSLT of >8 
minutes, one of whom remained wake during an entire 4 × 40 
minutes maintenance of wakefulness test (MWT). Finally, the 
identification of milder hypocretin deficiency and undisturbed 
nighttime sleep in patients with favorable evolution points to 
an association of this unusual disease course with differential 
clinical and neurobiological features.
In view of a ~10% frequency in the present cohort, marked 
improvement of EDS and other NT1 symptoms may not repre-
sent an exceptional finding, and similar cases could show up in 
other sleep centers with sufficiently large NT1 patient cohorts. 
In the absence of published accounts, our observation provides 
the opportunity to speculate about its pathophysiological, thera-
peutic, and diagnostic implications. From a pathophysiology 
perspective, it is tempting to link the observed spontaneous 
improvement with the emerging concept that sleep-wake-regu-
lating nuclei possess a potential of neuroplasticity, as indicated 
by increased numbers of histaminergic tuberomammillary neu-
rons in NT1 brains [23–25], and elevated blood levels of brain-
derived neurotrophic factor (BDNF) in NT1 patients [26–28]. In 
this context, our finding of progressive hypocretin deficiency in 
two patients suggests compensation mechanisms distinct from 
the hypocretin system, which warrants further studies.
As a potential explanation for the favorable disease course 
in patients with measurable hypocretin levels, higher numbers 
of surviving hypocretin neurons may more effectively compen-
sate for their reduced signaling, hypothetically by reinforcing 
synaptic strength to other target nuclei involved in sleep-wake 
regulation (e.g. histamine). The likelihood that this putative neu-
roplastic adaptation has clinical impact might be higher when 
hypocretin neurons are destroyed in a slowly progressive man-
ner, as was the case in two of our patients with follow-up CSF 
hypocretin measurements. A similar case was recently reported 
by Lopez et al. [29], describing a 17-year old NT1 patient with CSF 
hypocretin level of 106 pg/ml 1  year after the onset of sleepi-
ness and partial cataplexy, with remission of cataplexy within 
2 years despite further decrease of CSF hypocretin level to 27 pg/
ml. These observations thus expand the meaning of detectable 
CSF hypocretin levels in NT1, which has already been linked to 
longer mean sleep latencies on MSLT [30], and less fragmented 
nighttime sleep [31].
From a therapeutic perspective, it has been argued that 
immunotherapy, when administered in close relationship to 
disease onset, can interrupt, delay or even reverse the destroy-
ing process of the hypocretin neurons [32, 33]. Future stud-
ies must evaluate whether NT1 patients with detectable CSF 
hypocretin levels—both with and without spontaneous clinical 
improvement—may still benefit from immunotherapy when 
given many years after disease onset. Increased recognition of 
this NT1 subgroup is warranted yet challenging, because detect-
able CSF hypocretin levels have been identified as predictor of a 
longer diagnostic delay [34, 35].
This work has several limitations. In addition to its retro-
spective design and small number of included NT1 patients, we 
must acknowledge that we did not perform urinary drug screen-
ing during MSLT/MWT and, hence, may have missed underhand 
consumption of psychostimulants, with the intention to avoid 
social/work-related restrictions or being banned from driving 
[36]. Second, although the employed radioimmunoassay kit for 
hypocretin-1 has a low inter- and intra-assay variability [19, 37, 
38], its accuracy might be less reliable when CSF hypocretin lev-
els are below 60 pg/ml, and the applied CSF hypocretin detection 
limit of 30 pg/ml might thus appear as too low. However, the 
identification of milder CSF hypocretin deficiency as an inde-
pendent predictor of EDS improvement seems to justify such a 
low detection level and suggests that undetectable and very low 
CSF hypocretin levels possess differential clinical and prognos-
tic value. In addition, another study in NT1 patients observed 
significant hypocretin-dependent differences in sleep fragmen-
tation when using the same CSF hypocretin detection level 
of 30 pg/ml [31]. Third, by including only patients with stable 
therapy we could have introduced a selection bias, neglecting 
patients requiring frequent therapy modifications. Thus, our 
results cannot be generalized to all NT1 patients, and we might 
have overestimated the number of patients with spontaneous 
improvement. Finally, some of the patients revealed atypical 
features such as high sleep efficiency or long R sleep latency on 
polysomnography. These findings may raise suspicion about the 
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diagnosis of NT1, but all patients were diagnosed with positive 
hypocretin, HLA and MSLT criteria. It seems, however, possible 
that these patients somehow reflect an alternative phenotype 
of NT1.
In conclusion, spontaneous improvement akin to clinical 
remission—a hitherto almost unthinkable scenario in NT1 
patients, though representing a well-known feature in many 
other autoimmune disorders of the nervous system—seems to 
occur in a minority of NT1 patients. NT1 patients with detect-
able CSF hypocretin levels and non-fragmented nocturnal sleep 
might constitute a target subgroup with differential prognosis 
and therapeutic requirements. Thus, our observation raises 
some hope that the natural course of NT1 may not be as adam-
antly persistent we believed as yet. Replication in a prospect-
ive study with a larger number of patients is warranted, ideally 
applying novel tools to better monitor the disease course both 
subjectively (e.g. with validated questionnaires reflecting the 
whole range of NT1 symptoms [39]) and objectively (e.g. with 
laboratory-based cataplexy documentation [40]).
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